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Abstract
Purpose The aims were to evaluate the construct validity and reliability of the Dutch version of the pediatric-modified Total
Neuropathy Score (ped-mTNS) for assessing vincristine-induced peripheral neuropathy (VIPN) in Dutch pediatric oncology
patients aged 5–18 years.
Methods Construct validity (primary aim) of the ped-mTNS was determined by testing hypotheses about expected correlation
between scores of the ped-mTNS (range: 0–32) and the Common Terminology Criteria for Adverse Events (CTCAE) (range: 0–
18) for patients and healthy controls and by comparing patients and controls regarding their total ped-mTNS scores and the
proportion of children identified with VIPN. Inter-rater and intra-rater reliability and measurement error (secondary aims) were
assessed in a subgroup of study participants.
Results Among the 112 children (56 patients and 56 age- and gender-matched healthy controls) evaluated, correlation between
CTCAE and ped-mTNS scores was as expected (moderate (r = 0.60)). Moreover, as expected, patients had significantly higher
ped-mTNS scores and more frequent symptoms of VIPN compared with controls (both p < .001). Reliability as measured within
the intra-rater group (n = 10) (intra-class correlation coefficient (ICCagreement) = 0.64, standard error of measurement
(SEMagreement) = 2.92, and smallest detectable change (SDCagreement) = 8.1) and within the inter-rater subgroup (n = 10)
(ICCagreement = 0.63, SEMagreement = 3.7, and SDCagreement = 10.26) indicates insufficient reliability.
Conclusion The Dutch version of the ped-mTNS appears to have good construct validity for assessing VIPN in a Dutch pediatric
oncology population, whereas reliability appears to be insufficient and measurement error high. To improve standardization of
VIPN assessment in children, future research aimed at evaluating and further optimizing the psychometric characteristics of the
ped-mTNS is needed.
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Introduction
Vincristine (VCR) is a chemotherapeutic agent which is often
used in pediatric oncology for the treatment of various hemato-
logical and solid cancers [1].A frequently occurring side-effect
of VCR is peripheral neuropathy [2]. VCR-induced peripheral
neuropathy (VIPN) is amixed sensory, motor and autonomous
neuropathy mainly affecting the longer peripheral nerves.
Symptoms of VIPN usually start in the distal part of the limbs
andmay progress proximally [3]. Symptoms include paresthe-
sia,numbness, tingling, lossofproprioceptionandpain.Rarely,
VIPN may lead to profound muscle weakness with symptoms
as foot drop and walking difficulties. Autonomous symptoms
of VIPN include constipation and dizziness [4]. VIPN showed
to adversely affect quality of life in oncology patients [5].
VIPN is a multifactorial toxicity, which is influenced by
several determinants. Older children seem to be more affected
than younger children, whereas the influence of gender on
VIPN is unclear [6]. Moreover, there is a racial difference:
Caucasian children tend to have more VIPN than non-
Caucasian children [7]. Furthermore, although there is a dose
dependent relation between VCR and [8], studies assessing
associations between pharmacokinetic parameters of VCR
and VIPN report conflicting results [9, 10]. Finally, genetic
factors are known to influence susceptibility to VIPN, with
several pathways involved such as CEP72 and CYP3A4/5 [8,
11].
Treatment of VIPN is mainly symptomatic using analge-
sics such as gabapentin, or laxatives in case of constipation.
Another treatment option is dose reduction of VCR, although
this may lead to suboptimal treatment of the underlying ma-
lignancy [12].
In clinical practice, several tools are used to measure
VIPN in pediatric oncology patients. The Common
Terminology Criteria for Adverse Events (CTCAE) is a
tool that assesses the severity of several types of ad-
verse events in oncology patients [13], including those
regarding peripheral neuropathy, constipation and neu-
ralgia. Furthermore, Lavoie-Smith et al. [14, 15] devel-
oped the Total Neuropathy Score-Pediatric Vincristine
(TNS-PV) specifically for the assessment of VIPN in
pediatric oncology patients. The TNS-PV consists of a
seven-item interview-based questionnaire and a stan-
dardized physical examination (testing of vibration and
temperature sense, muscle strength and deep tendon re-
flexes (DTR)) [6]. Besides questionnaires and/or physi-
cal examinations, nerve conduction studies in which the
conduction velocity of different nerves is measured
using somatosensory evoked potentials [16, 17] can also
be used to assess VIPN.
However, all of the above-mentioned methods to assess
VIPN have some limitations. Although frequently used, the
CTCAE shows insufficient sensitivity in detecting motor and
sensory neuropathy [2]. Moreover, the TNS-PV can only be
used in children aged 6 years or older [14]. Furthermore, nerve
conduction studies are invasive, painful, and expensive [14].
Finally, physical examination can only validly be performed
and interpreted by specifically trained physicians such as pe-
diatric neurologists [18, 19].
Recently, the pediatric-modified Total Neuropathy
Score (ped-mTNS) was developed [20]. This instrument,
which consists of an interview-based questionnaire and
physical examination, showed to have superior psycho-
metric characteristics compared with other tools for the
assessment of peripheral neuropathy in children [2].
Moreover, it is a quick, inexpensive, and non-invasive
tool that can be employed by different health care profes-
sionals, such as physicians, physical therapists, and nurses
[4]. However, the psychometric characteristics of the ped-
mTNS have solely been evaluated in North American
children with cancer aged 5–18 years.
The primary aim of the current study was to evaluate the
construct validity of the Dutch version of the ped-mTNS for
the assessment of VIPN in Dutch pediatric oncology patients
aged 5–18 years. In addition as secondary aim, reliability of
this tool was investigated in a subpopulation.
Methods
Study population
The study population of this multicenter cross-sectional
study consisted of pediatric oncology patients aged 5–18
years with non- non central nervous system (CNS) malig-
nancies and healthy controls.
Patients were eligible for study participation if they
were treated with at least four administrations of at least
1.5 mg/m2 (maximum 2 mg) VCR within a period of 6
weeks during treatment of their current malignancy.
VIPN assessments were performed within the time
frame of at least one month after start of VCR therapy
and two months after cessation of VCR therapy maxi-
mally. This resulted in the inclusion of patients with the
following diagnoses and treatment protocols for the cur-
rent study: acute lymphoblastic leukemia (ALL) (DCOG
ALL-11 protocol [21]), Hodgkin lymphoma (EuroNet-
PHL-C1 pro toco l [22 ] or C2 pro toco l [23 ] ) ,
nephroblastoma (SIOP Wilms 2001 protocol [24]), and
rhabdomyosarcoma (EpSSG RMS 2005 protocol [25]).
VCR was administered either by means of a bolus in-
jection (1–5 min) or a 1-h infusion. The healthy control
group consisted of siblings of participating patients and
children known to hospital co-workers (relatives or
friends). Controls were age- (± 1 year) and gender-
matched to the patients on a 1:1 basis. Patients and
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controls were excluded in case of premorbid develop-
mental disorders, neuromuscular disorders, lower ex-
tremity amputations, diabetes mellitus, or in case they
were not able to speak or understand the Dutch lan-
guage. Although strictly speaking the included controls
could not develop VIPN (as they did not receive any
VCR), hypothetically they may have some degree of
peripheral neuropathy. The ped-mTNS is a tool which
assesses peripheral neuropathy, either chemotherapy-
induced or not, in children. For reasons of clarity, we
use the term VIPN in the remainder of this paper, there-
by referring to either VCR-induced (patients) or non-
VCR-induced (controls) peripheral neuropathy.
ped-mTNS
The original, English version of the ped-mTNS was trans-
lated into Dutch by a non-native English speaker, follow-
ed by a translation back to English by a bilingual Dutch-
English speaker. Subsequently, this back-translated ver-
sion was sent to the principal investigator of the original
ped-mTNS in the USA [4] in order to have it reviewed
and checked by its original developer. Appendix A and B
as Supplementary Materials contain the original version
and the Dutch version of the ped-mTNS as approved by
the developer, respectively.
The questionnaire-part of the ped-mTNS contains eight
questions about sensory, functional and autonomic symp-
toms. These questions were read out aloud by the assessor
to the participant. In addition, five different aspects of
VIPN were assessed by physical examination: light-touch
sensation by Semmes-Weinstein monofilaments (Rolyan–
Ability One, Germantown, WI, USA) [4, 26], pin sensibil-
ity by Medipin™ (Ltd, Hertfordshire, UK) [4], muscle
strength by means of manual muscle testing (graded ac-
cording to the Medical Research Council guidelines) [4,
27], and DTR of the Achilles and patella (graded according
to the Mayo Clinic Criteria) [4, 28]. Due to the unavailabil-
ity of a Biothesiometer™ (Biomedical Instruments,
Newbury, OH, USA) in The Netherlands, the assessment
of vibration sense was carried out with a Rydel-Seiffer 64-
Hz tuning fork (Gebrueder Martin, Tuttlingen, Germany),
which showed to be a valid instrument in the assessment of
vibration sense in children [4, 29]. For all items in the
questionnaire and the physical examination part, the score
ranged between 0 (no symptoms) and 4 (severe symptoms).
The worst scores within each of the 3 items as assessed by
the questionnaire, together with the scores of the 5 items
tested in the physical examinations, are used to calculate
the total ped-mTNS score, which is the sum of these 8
scores (range 0 to 32). Children with a total ped-mTNS
score of 5 or higher were considered to have VIPN [4].
CTCAE
The CTCAE (version 4.03) [13] consists of over 330 items
scoring adverse events due to cancer treatment divided into 26
different categories. Possible grades range from 0 (no symp-
toms) and 3 (severe symptoms) or, if the adverse event can be
deadly, category 4 is life threatening and category 5 is death.
The CTCAE items used for the assessment of VIPN are con-
stipation, peripheral sensory neuropathy, peripheral motor
neuropathy, and neuralgia. The maximum CTCAE sum score
of these 4 items is 18. Participants with a total score of 2 or
higher are considered to have VIPN [6]. The assessor asked to
which extent the participants experienced problems as de-
scribed in the relevant CTCAE items. For the item peripheral
sensory neuropathy, additionally DTR of the patella and
Achilles were assessed.
Procedures
Patients were included in Emma Children’s Hospital/
Amsterdam University Medical Centers and Sophia
Children’s Hospital/Erasmus Medical Center Rotterdam.
Study measurements were performed between September
2016 and July 2017. All study participants (patients and con-
trols) were tested once using both the ped-mTNS and CTCAE
to assess VIPN. These measurements were performed by the
same assessor (SS), who was trained extensively by a pediatric
neurologist to perform the VIPN assessments. Furthermore, a
subset of randomly selected patients and healthy controls were
assessed twice in order to assess intra-rater ((5 patients and 5
controls), both measurements performed by the same assessor)
and inter-rater reliability ((7 patients and 3 controls) second
measurement performed by a different assessor (MvdV), who
was also specifically trained for the study measurements). All
patients were measured during regular hospital visits. Healthy
controls were measured either during family visits in the hos-
pital or at home. For the assessment of intra-rater reliability, an
interval of 4–16 days between the two measurements, without
VCR administrations in between, was adhered to.
Statistics
Assessment of construct validity was determined by calculat-
ing the correlation between the ped-mTNS and the CTCAE
sum scores in patients as well as the actual differences be-
tween these scores. We hypothesized total ped-mTNS and
total CTCAE scores to be moderately correlated, since some
items between the two systems attempt to measure the same
items (peripheral motor neuropathy and peripheral sensory
neuropathy), whereas some items are only present in one of
the instruments (constipation is only an item in the CTCAE
and not in the ped-mTNS). Moreover, we expected to assess a
higher correlation between the two measurement tools than
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the correlationmeasured in the studyofGilchrist et al. (r=0.07)
[2], since in that study the CTCAE scores were retrieved from
medical records instead of the prospective assessment of
CTCAE scores used in our study. Either the Spearman or
Pearson correlation coefficients were calculated, depending
on normality of data distribution. According to Nunnally and
Bernstein [30], an ICC of > 0.70 was considered as good.
Furthermore, a correlation of 0.51–0.69 was considered mod-
erate and<0.5 as low [31].Wehypothesizedped-mTNSscores
of patients to be significantly higher compared with healthy
controls and the proportion of patients with VIPN to be signif-
icantly higher than those of healthy controls. Differences be-
tweenmeantotalped-mTNSscoreofpatientsandcontrolswere
analyzed using a Mann-Whitney U test. Differences between
the proportion of patients and controls who were identified as
having VIPN by the ped-mTNS were calculated using a Chi-
square test. A two-tailed significance level of 0.05 was used.
Assessment of reliability and standard error of measurement
of the ped-mTNS (secondary aims) was carried out as follows.
Reliability and measurement error were measured within the
inter-rater and intra-rater subgroups by means of intra-class cor-
relation coefficient using the two-way random effects model for
agreement (ICCagreement) according to the equation ICCagreement
= σp
2
σp2þσo2þσresidual2 where σe r r o r
2 = σo
2 + σ r e s i dua l
2 [32] .
Measurement error was assessed by calculating the standard
error of measurement from the same model (i.e., the two-way
random effects model for agreement (SEMagreement)) by the
equation SEMagreement ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
σo2 þ σresidual2ð Þ
p
and by calculat-
ing the smallest detectable change (SDCagreement) using the equa-
tion SDCagreement ¼ 1:96
ﬃﬃﬃ
2
p  SEMagreement [33, 34].
Dichotomized total scores of the ped-mTNS (yes/no VIPN;
a total ped-mTNS score of 0–4 indicates no VIPN and a score
of ≥ 5 indicates VIPN according to published data by Gilchrist
et al. [4]) were used to measure agreement in a 2 × 2 table to
calculate positive agreement (PA) (PA = 2a/(2a + b + c) and
negative agreement (NA) (NA = 2d/(2d + b + c).
All results on reliability are reported for patients, healthy con-
trols, and total group separately. All statistics were performed
using SPSS for Windows version 22.0 (SPSS, Chicago, IL).
Results
Study population
Fifty-six patients and 56 healthy controls (median, interquar-
tile range (IQR) age 9.6 (6.6–14.2) years) were included in the
study. Characteristics of the participants are presented in
Table 1. The majority of the patients were treated for ALL
(n = 39, 70%) or Hodgkin lymphoma (n = 12, 21%). The
mean (standard deviation (SD)) cumulative dose of VCR ad-
ministered to the patients was 19.6 mg/m2 (13.9).
Construct validity of the ped-mTNS
The correlation between total scores of the ped-mTNS and
CTCAE was moderate as expected in patients (r = 0.60).
Patients had a significantly higher score on ped-mTNS than
healthy controls (median (IQR): 10.0 (6.25–13.0) and median
(IQR): 0.0 (0.0–1.0), respectively; p < 0.001) (Table 2).
Furthermore, patients were significantly more often identified
as having VIPN (≥ 5 on the ped-mTNS) than healthy controls
(86% versus 1.8%, respectively; p < 0.001).
Reliability
All results regarding reliability for patients, healthy controls,
and the total group of participants are depicted in Table 3. The
different variance components of the intra-rater reliability
group were: σp
2 = 15.3, σo
2 = 0, and σresidual
2 = 8.6 and those
of the inter-rater reliability were: σp
2 = 23.1, σo
2 = 0, and
σresidual
2 = 13.7. The ICCagreement of the intra-rater group was
0.64, whereas this was 0.63 of the inter-rater group. Positive






Male 32 (57.1) 32 (57.1)
Female 24 (42.9) 24 (42.9)
Age in years (median [IQR]) 9.7 [6.3–14.1] 9.6 [7.0–14.4]
Ethnicity
European 40 (71.4) 39 (69.6)
Middle-Eastern 10 (17.9) 6 (10.7)
African 1 (1.8) 4 (7.1)
Hispanic 4 (7.1)
Other 5 (8.9) 3 (5.4)
Diagnosis2
ALL 39 (69.6)
Hodgkin lymphoma 12 (21.4)
Nephroblastoma 1 (1.8)
Rhabdomyosarcoma 4 (7.1)
Administration method of VCR2
Bolus injection 47 (83.9)
1-h infusion 9 (16.1)
Cumulative dose of VCR
(mg/m2; mean (SD))2
19.6 (13.91)
Time since last VCR do se (days,
median [IQR])2
9.5 [0.75–21.0]
1 Values represent the number (%) of participants, unless indicated other-
wise; 2 This is only applicable to the patient population
IQR interquartile range, ALL acute lymphoblastic leukemia, VCR vincris-
tine, SD: standard deviation
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agreement was 80%, negative agreement was 83%. Positive
agreement and negative agreement of inter-rater reliability
were both 100%. Finally, the SEMagreement within the intra-
rater group was 2.92 and within the inter-rater group 3.7. The
SDCagreement was 8.1 within the intra-rater group and 10.26
within the inter-rater group.
Discussion
In this study, theDutch version of the ped-mTNSwas validated
by assessing VIPN in a cohort of Dutch pediatric oncology
patients aged 5–18 and age- and gender-matched healthy con-
trols. The correlation between ped-mTNS and CTCAE was
found to be as expected (i.e., moderate). Furthermore, patients
had significantly higher ped-mTNS scores than controls and
were significantly more often identified as having VIPN.
These results indicate that this translated version of the ped-
mTNS has good construct validity regarding the assessment
of VIPN in Dutch pediatric oncology patients. However, reli-
ability of this instrument was insufficient (ICCagreement < 0.7).
The outcomes of measurement error showed a SEMagreement of
2.92 and 3.7 and a SDCagreement of 8.1 and 10.26 for the intra-
rater and inter-rater subgroups, respectively.Although themin-
imal important change (MIC) of this instrument is unknown,
these SEMagreement and SDCagreement scores appear to be rather
high, given the fact that scores can range from 0 to 32 and we
used a cutoff value of ≥ 5 to discriminate children with and
without VIPN. However, positive agreement and negative
agreement were good, with scores between 80 and 100% for
intra-rater and inter-rater reliability, respectively.
The results of the current study are comparable to a previ-
ous study. Gilchrist et al. [4] recently showed that patients had
a significantly higher score on ped-mTNS than healthy con-
trols (mean (SD): 8.7 (4.2); and 1.4 (0.9), respectively).
However, in that study, only 9.8% of the controls had a score
of 0 on the ped-mTNS, while this percentage was 68% in the
current study. This discrepancy canmost likely be attributed to
differences in carrying out the assessments with the ped-
mTNS, such as the level of training of the assessors, and not
to a difference in population. The results of Gilchrist et al.
showed that healthy controls frequently experienced some
disorders of motor function, autonomic symptoms, pin sensa-
tion, and distal strength, although in both studies scores of
healthy individuals were not high enough to indicate VIPN
(ped-mTNS score was < 5) and therefore not of great clinical
relevance. In the current study, the healthy control group had a
mean (SD) ped-mTNS score of 0.9 (1.5). In the study of
Gilchrist et al., similar scores were reported (mean (SD): 1.4
(0.9)). Furthermore, the current study showed an ICCagreement
score of the ped-mTNS for intra- and inter-rater reliability of
0.64 and 0.63, respectively. These scores are lower than the
ICC sores for intra-rater and inter-rater reliability as reported
by Gilchrist et al. (0.99 and 0.98, respectively) [4]. This may
be due to the fact that within the study of Gilchrist et al., an
interval of only 1 h between two measurements was applied
Table 3 Reliability outcome measures of the pediatric-modified Total Neuropathy Score
ICCagreement total
ped-mTNS score
95% CI ICC total
ped-mTNS score






Inter-rater reliability patients (n = 7) 0.45 − 0.43 to 0.88 12.25 4.42 100% 100%
Inter-rater reliability healthy
controls (n = 3)
0 - 5.73 2.07 - 100%
Intra-rater reliability patients (n = 5) 0 − 1.3 to 0.20 8.96 3.23 80% 0%
Intra-rater reliability healthy
controls (n = 5)
0 - 0 0 - 100%
Inter-rater reliability total (n = 10) 0.63 0.04 to 0.89 10.26 3.7 100% 100%
Intra-rater reliability total (n = 10) 0.64 0.06 to 0.90 8.1 2.92 80% 83%
ICC intra-class correlation coefficient, ped-mTNS pediatric-modified Total Neuropathy Score, CI confidence interval, SDC smallest detectable change,
SEM standard error of measurement








Median [IQR] 10.0 [6.25–13.0] 0.0 [0.0–1.0] < 0.001
Score of 0–4 (n, (%)) 8 (14.3) 55 (98.2)
Score 5–32 (n, (%)) 48 (85.7) 1 (1.8)
Total CTCAE scores
Median [IQR] 3 [2–4.75] 0 [0–0] < 0.001
Score of 0–1 (n, (%)) 9 (16.1) 55 (98.2)
Score of 2–4 (n, (%)) 33 (59.0) 1 (1.8)
Score of 5–7 (n, (%)) 12 (21.4) 0 (0)
Score of 8–18 (n, (%)) 2 (3.6) 0 (0)
ped-mTNS pediatric-modified Total Neuropathy Score, IQR inter-
quartile range CTCAE Common Terminology Criteria for Adverse
Events
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when assessing inter- and intra-rater reliability, whereas in our
study, this interval was 4 days minimally. An interval of 1 h
may have led to recall bias of the patient for the interviewed
questions and of the assessor for the physical examination
part, since there is a high chance that the results of the previous
measurement are memorized. Furthermore, Gilchrist et al.
have used a two-way mixed effect model for consistency for
their calculation of ICC (i.e. ICCconsistency); therefore, the var-
iance due to systematic differences between observers was
ignored [32, 33]. By using ICCagreement, which we did in our
study, this variance of observers was taken into account.
However, using ICCconsistency instead of ICCagreement leads to
higher ICC values, which could be an explanation for the
difference in results between these studies [35].
Our study was the first to evaluate psychometric character-
istics of a translated version of the ped-mTNS. Our results are
important both for clinical purposes and research practice as
they contribute to the urgently needed standardization of mea-
suring peripheral neuropathy in children with cancer using
high-quality outcome measurement instruments.
This study has some limitations. As previously mentioned,
the Rydel-Seiffer 64-Hz tuning fork was used for the assess-
ment of vibration sense instead of the Biothesiometer™, due to
unavailability of this device in The Netherlands. However, ac-
cording to Hilz et al. [29], the Rydel-Seiffer 64-Hz tuning fork
is a valid instrument to examine vibration sense and Gilchrist
et al. [20] showed a moderate to good correlation (i.e., r = −
0.62 to − 0.73, depending on test site) between the
Biothesiometer™ and the Rydel-Seiffer 64-Hz tuning fork.
The assessment of reliability and measurement error were
only evaluated within a subgroup of 20 participants. Although
there is no formal consensus about the minimal number of
participants needed to properly asses the inter- and intra-
rater reliability [36], the number of participants included for
these assessments is probably rather low as can be seen in the
95% confidence intervals of the reliability estimations, due to
logistical limitations. Therefore, these results should be
interpreted with caution. Future studies assessing the reliabil-
ity of the ped-mTNS in a larger group of patient are advocated.
These studies can be performed within a patient population,
since results regarding reliability of healthy controls will prob-
ably be difficult to interpret due to floor effects.
Despite certain psychometric limitations, the ped-mTNS is
currently considered to be the most optimal instrument for
assessing VIPN in children compared with other instruments
[37]. Continuous efforts should be made to further improve
this instrument, by studying and advancing its reliability and
by additionally assessing its validity. Specifically, more re-
search should be undertaken to investigate the content validity
of this instrument, by assessing if the ped-mTNS is complete
in measuring all the aspects of VIPN in terms of relevance and
comprehensibility of this instrument, both for patients and
assessor. Finally, it should be investigated to which extent an
adapted version of the ped-mTNS could be developed that is
suitable for assessing VIPN in children under the age of 5. All
above-mentioned efforts may result in a more valid and reli-
able instrument for the assessment of VIPN in children.
Meanwhile, using the current version of the ped-mTNS is
advocated since it will lead to more uniformity in assessing
VIPN in children with cancer, thereby enabling the compari-
son of study results for this group of patients [37].
In conclusion, the current study showed that the Dutch
translated version of the ped-mTNS has good construct valid-
ity, whereas reliability appeared insufficient, although patient
numbers for reliability testing were low. In order to improve
the comparability of results across different studies investigat-
ing VIPN in children, further standardization of VIPN assess-
ment is needed. More research aimed at investigating and
improving the quality of the ped-mTNS, or in the develop-
ment of another instrument to assess VIPN, is needed. This
will ultimately lead to a robust instrument and more uniformi-
ty in evaluating chemotherapy-induced peripheral neuropathy
in children with cancer.
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